Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.56 |
| ▸ | CNR2 | P34972 | 7/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684239 | 0.98 | CNR1 (0.57) | CNR1CNR2HTTHSD17B10MEN1 | |
| Adamantane SCHEMBL27759633 | 0.89 | CNR2 (0.70) | CNR1CNR2HTTHSD17B10MEN1 | |
| SCHEMBL27760017 | 0.87 | CNR2 (0.64) | CNR1CNR2HTTHSD17B10MEN1 | |
| SCHEMBL23889217 | 0.86 | CNR1 (0.56) | CNR1CNR2HTTHSD17B10MEN1 | |
| SCHEMBL16063426 | 0.85 | CNR1 (0.54) | CNR1CNR2HTTHSD17B10MEN1 | |
| Lithium Ion SCHEMBL1078086 | 0.83 | CNR2 (0.56) | CNR1CNR2HTTHSD17B10MEN1 | |
| SCHEMBL5782959 | 0.83 | MDM2 (0.54) | HTTHSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL20647071 | 0.82 | CNR1 (0.54) | CNR1CNR2HTTHSD17B10MEN1 | |
| SCHEMBL22641005 | 0.82 | CNR2 (0.52) | CNR1CNR2HTTHSD17B10MEN1 | |
| SCHEMBL4961512 | 0.82 | CNR1 (0.55) | CNR1CNR2HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835436-B2 | Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2014-09-16 | — | — | US | disclosed |
| US-20120115881-A1 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-05-10 | — | — | US | disclosed |
| WO-2011005052-A2 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN GROSS CORPORATION (KR) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115881-A1 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HTR2C, HTR5A, HTR2A | CNR1 90/4885CNR2 27/4885HTT 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.